{"version":"1.0","type":"link","title":"Cost-effectiveness analysis of capivasertib plus fulvestrant in the -altered subgroup with HR+/HER2- advanced breast cancer: a United States payer perspective.","author_name":"Liang X 외","author_url":"https://prs-insight.online/author/Liang%20X","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/74535","thumbnail_width":1200,"thumbnail_height":630}